

Botulinum Toxin for the Treatment of Involuntary Movement Disorders

NCT00001208

Status	RECRUITING
Sponsor	National Institute of Neurological Disorders and Stroke (NINDS)
Enrollment	2,000 participants

Key Eligibility Criteria

Inclusion (2)

- Patients 2 years and older, will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
- Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.

Exclusion (3)

- Women who are planning on becoming pregnant, are pregnant or breastfeeding, for the duration of the condition.
- Subjects who require treatment with an aminoglycoside antibiotic, until treatment is complete.
- For laryngeal injections, subjects must have a paradoxical vocal fold movement with intermittent stridor due to either gastroesophageal reflux or emotional disorders

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States